



Freedom of Information Team  
De La Court House  
Queen Alexandra Hospital  
Southwick Hill Road  
Portsmouth  
Hampshire  
PO6 3LY

Name:  
Email:  
Date: 07/08/2023  
Ref: 23-24 259

Dear

**RE: Freedom of Information request**

Thank you for your request for information under the Freedom of Information Act 2000, which was received by the Trust on 26/07/2023. Please see responses to your requests below.

**Q1. In the last 3 months, how many patients have been initiated\* on the following agents for the treatment of melanoma?**

Please see table below.

Data range is from our latest validated data (Jan 23 – March 23).

<b>Ipilimumab (monotherapy)</b>	0
<b>Nivolumab (monotherapy)</b>	15
<b>Nivolumab AND Ipilimumab (combination)</b>	<5
<b>Pembrolizumab</b>	26
<b>Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)</b>	<5
<b>Other active systemic anti-cancer therapy</b>	<5

We are unable to provide precise figures when these are less than five due to the risk that individuals will be identified, as we are required to protect their identity under the Data Protection Act.

In such circumstances sections 40(2) and (3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle. This states that personal data should be processed fairly and lawfully. It is the fairness aspect of this principle which, in our view, would be breached by disclosure.

**Q2. In the last 3 months, how many patients have been initiated\* on the following agents for the treatment of renal cell carcinoma?**

Please see table below.

Data range is from our latest validated data (Jan 23 – March 23).

<b>Nivolumab (monotherapy)</b>	10
<b>Nivolumab + Ipilimumab</b>	5
<b>Nivolumab + Cabozantinib</b>	0
<b>Avelumab + Axitinib</b>	<5

Please see exemption in question 1.

**Q3. In the past 3 months, how many patients have been initiated\* on the following agents for the treatment of gastric, gastro-oesophageal junction or oesophageal cancer:**

Please see table below.

Data range is from our latest validated data (Jan 23 – March 23).

<b>Nivolumab monotherapy or in combination with Ipilimumab</b>	<5
<b>Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)</b>	<5
<b>Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)</b>	0

Please see exemption in question 1.

Please accept this letter as completion of your request. Please note that copies of this request will be held on file for three years before being confidentially destroyed.

If you are dissatisfied with the outcome of your request, please contact our Head of Information Governance on [Information.Governance@porthosp.nhs.uk](mailto:Information.Governance@porthosp.nhs.uk) or write to the above address and we will conduct an internal review. Upon review, if you are still dissatisfied, you may appeal our decision by contacting the Information Commissioner's Office; for more information, please visit the [ICO's website](#).

Please be aware, if we do not receive an appeal within 30 days of you receiving this letter, we will assume that you are satisfied with our response. If you have any further queries, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team